Question explored with the scientific record
is statin good for me
The short version: statins reduce heart attacks and strokes in people who already have vascular disease, but the benefit for healthy people is small and comes with a real diabetes risk.
The evidence here is almost entirely about people with established disease or very high risk. For secondary prevention — after a heart attack, stroke, or bypass surgery — the numbers are consistent. A meta-analysis of 14 randomized trials found statins cut all-cause mortality by about 24% (OR 0.76) and nonfatal heart attacks by 34% (OR 0.66) [20]. In patients with peripheral artery disease, all-cause mortality dropped by about 40% (OR 0.60) [18]. For heart transplant recipients, the mortality reduction was even larger, with an odds ratio of 0.26 [25]. These are real effects in sick populations.
For primary prevention — healthy people without known disease — the picture is different. A large Israeli cohort of new statin users over 70 found a 29% reduction in MACE (HR 0.71) but no significant diabetes increase in that age group [10]. Younger adults got a smaller cardiovascular benefit (HR 0.80) and a clear diabetes risk: adherence to statins raised new-onset diabetes by about 20% (HR 1.20) in prediabetic patients [4], and high-intensity statins like rosuvastatin 20 mg pushed diabetes incidence to 8.3% versus 5.8% for moderate doses [12]. The absolute risk increase for diabetes is roughly 0.5% per year of treatment [30, 31], which partly offsets the cardiovascular gain in low-risk people.
The mechanism matters here through the colloidal lens. Statins lower LDL cholesterol, but they also impair insulin signaling in pancreatic beta cells and reduce GLUT-4 transport, which raises blood sugar [31]. That is a direct metabolic trade-off, not a side effect you can ignore. The U-shaped mortality curve for non-HDL cholesterol — where both very low and very high levels increase death risk — suggests that driving LDL below about 100 mg/dL may be harmful in people without established disease [17]. The optimal non-HDL range for all-cause mortality was around 142-144 mg/dL, not the near-zero targets the guidelines push.
| Population | Outcome | Statin effect | Diabetes risk |
|---|---|---|---|
| Secondary prevention (post-heart attack) | All-cause mortality | OR 0.76 [20] | ~0.5%/yr increase [30] |
| Peripheral artery disease | All-cause mortality | OR 0.60 [18] | Not reported |
| Primary prevention, age ≥70 | MACE | HR 0.71 [10] | Not significant [10] |
| Primary prevention, age <70 | MACE | HR 0.80 [10] | HR 1.20 for NODM [4] |
| High-intensity vs moderate statin | MACE | 11.6% vs 14.1% [12] | 8.3% vs 5.8% NODM [12] |
My call: if you have had a heart attack, stroke, or bypass surgery, the evidence supports statin therapy with moderate confidence. If you are a healthy person with no vascular disease and your doctor is offering a statin for primary prevention, the benefit is small, the diabetes risk is real, and the evidence does not clearly favor starting it — especially at high doses. Confidence: moderate for secondary prevention, low for primary prevention in healthy individuals.
Sources examined 32
-
CORONARY VASCULAR DYSFUNCTION IS ASSOCIATED WITH INCREASED EPICARDIAL ADIPOSE TISSUE AND MAJOR ADVERSE CARDIOVASCULAR EVENTS
This study investigates the relationship between impaired coronary artery distensibility index (CDI), increased epicardial adipose tissue (EAT), and the incidence of major adverse cardiovascular events (MACE) in a cohort of statin-therapy patients.
DOI: 10.1016/s0735-1097(12)62102-0 -
Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events
A critical synthesis of major omega-3 trials (notably REDUCE-IT vs STRENGTH) assessing whether EPA-only therapy (icosapent ethyl) reduces major adverse cardiovascular events, and discussing how drug formulation, dose, and placebo choice influence outcomes and implications for AS…
DOI: 10.1001/jama.2020.22387 -
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
In adults with diabetes, initiating a statin–ezetimibe combination with a lower-intensity statin reduces major adverse cardiovascular events and myocardial infarction compared with high-intensity statin monotherapy, while lowering liver- and diabetes-related hospitalizations in …
DOI: 10.4093/dmj.2024.0482 -
Risk of New-Onset Diabetes Mellitus Versus Reduction in Cardiovascular Events With Statin Therapy
This study investigates the risk of new-onset diabetes mellitus (NODM) and the reduction of major adverse cardiovascular events (MACE) in prediabetic patients undergoing statin therapy, finding that while statins increase the risk of NODM, they significantly reduce MACE, suggest…
DOI: 10.1016/j.amjcard.2013.10.043 -
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
This systematic review and meta-analysis evaluates the efficacy and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease, finding significant improvements in lipid profiles and reductions in all-cause mortality and major adverse cardiovascul…
DOI: 10.1002/cpt.1859 -
Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study
In Korean patients with type 2 diabetes on statins, longer statin therapy duration was the strongest predictor of lower major adverse cardiovascular event risk, followed by achieved LDL-C level and statin intensity.
DOI: 10.1186/s12933-022-01466-z -
C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy
This study investigates the relationship between C-reactive protein (CRP) levels and coronary atheroma regression and cardiovascular events in patients undergoing maximally intensive statin therapy, finding that nonincreasing CRP levels are associated with greater atheroma regre…
DOI: 10.1161/CIRCULATIONAHA.113.004243 -
Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery
This study investigates the impact of early statin therapy on clinical outcomes, demonstrating that initiating statin use within one month after coronary artery bypass graft (CABG) surgery significantly reduces the risk of all-cause mortality and major adverse cardiovascular eve…
DOI: 10.1161/circulationaha.108.799445 -
Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)
A multicenter, randomized, double-blind, placebo-controlled trial in acute coronary syndrome showed that initiating fluvastatin 80 mg at hospital admission did not change inflammatory biomarkers (CRP, IL-6, PAPP-A) over 2–30 days but significantly reduced one-year major adverse …
DOI: 10.1186/1745-6215-11-61 -
Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality
In a large Israeli population-based cohort of new statin users without cardiovascular disease or diabetes, adherence to statin therapy for primary prevention in the elderly (≥70 years) was associated with reduced major adverse cardiovascular events and all-cause mortality withou…
DOI: 10.1016/j.amjmed.2020.09.058 -
Standard-Dose Statin Therapy Provides Incremental Clinical Benefits in Normocholesterolemic Diabetic Patients
This study investigates the effects of standard-dose statin therapy on cardiovascular outcomes in normocholesterolemic diabetic patients, demonstrating significant clinical benefits compared to non-statin therapy.
DOI: 10.1253/circj.cj-09-0243 -
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Cardiovascular Risk Assessment and Hyperlipidemia
This article reviews the identification and risk stratification of patients at risk for coronary artery disease (CAD) and the management of their lipid levels, emphasizing the pivotal role of healthcare providers in treatment decisions.
DOI: 10.1016/j.ccell.2008.03.014 -
The pharmaco‐economics of peri‐operative statin therapy
This study analyzes the cost-effectiveness of peri-operative statin therapy in patients undergoing major elective vascular surgery, suggesting it may be the most cost-effective use of statins due to a favorable number-needed-to-treat of 15 for preventing adverse cardiovascular e…
DOI: 10.1111/j.1365-2044.2005.04371.x -
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
This study evaluates the cost-effectiveness of PCSK9 inhibitors in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, finding that their use does not meet acceptable cost-effectiveness thresholds at 2015 prices and would significa…
DOI: 10.1001/jama.2016.11004 -
Continuation of Statin Treatment and All-Cause Mortality
This population-based cohort study evaluates the impact of statin therapy on all-cause mortality among patients with and without coronary heart disease, finding that better continuity of treatment significantly reduces mortality risk.
DOI: 10.1001/archinternmed.2008.552 -
U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy
Non-HDL-C demonstrated a U-shaped relationship with all-cause and cardiovascular mortality in 12,574 US men without statin therapy, with lowest mortality risk at approximately 142-144 mg/dl.
DOI: 10.3389/fcvm.2022.903481 -
Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis
A systematic review and meta-analysis showing that statin therapy reduces all-cause mortality and stroke in patients with lower limb peripheral arterial disease, although evidence for cardiovascular mortality and myocardial infarction is less clear and overall study quality is l…
DOI: 10.1016/j.vph.2014.09.001 -
Relationships of Statin Therapy and Hyperlipidemia With the Incidence, Rupture, Postrepair Mortality, and All-Cause Mortality of Abdominal Aortic Aneurysm and Cerebral Aneurysm: A Meta-analysis and Systematic Review
Statin therapy was associated with reduced risks of abdominal aortic aneurysm rupture, postrepair mortality, all-cause mortality, and adverse events, and hyperlipidemia was associated with lower risk of cerebral aneurysm rupture, without increasing aneurysm incidence.
DOI: 10.1097/fjc.0000000000000653 -
Clinical Outcomes in Statin Treatment Trials
A comprehensive meta-analysis of randomized statin trials (≥1 year) showing that statin therapy reduces all-cause mortality and major cardiovascular events versus placebo, with variation in effect across statin types and study designs and notable overall applicability across pri…
DOI: 10.1001/archinte.159.15.1793 -
Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery
This study investigates the impact of the timing and dosage of preoperative statin therapy on 30-day all-cause mortality in patients undergoing coronary artery bypass graft surgery, finding that administration within 24 hours and doses greater than 20 mg significantly reduce mor…
DOI: 10.1016/j.athoracsur.2016.12.043 -
Preoperative statin therapy is associated with reduced 30-day postoperative all-cause mortality in patients undergoing coronary artery bypass surgery: A meta-analysis of large size observational studies
A meta-analysis of large-size observational studies (n=30,955) indicates that preoperative statin therapy is associated with a significant reduction in 30-day postoperative all-cause mortality after isolated coronary artery bypass grafting (CABG), with consistent findings across…
DOI: 10.1016/j.ijcard.2014.11.216 -
Meta-analysis of statin therapy in maintenance dialysis patients
This meta-analysis investigates the effects of statin therapy on major clinical outcomes in maintenance dialysis patients, revealing significant improvements in dyslipidemia and inflammatory markers but no impact on cardiovascular or all-cause mortality.
DOI: 10.3109/0886022x.2015.1061871 -
Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis
A meta-analysis of 12 cohort studies involving 162,252 people living with HIV found statin use associated with reduced all-cause mortality and cancer risk, but no significant association with cardiovascular events.
DOI: 10.3389/fmed.2021.769740 -
Impact of Statin Use After Heart Transplantation
This meta-analysis evaluates the impact of statin therapy on heart transplant recipients, demonstrating significant reductions in all-cause mortality, hemodynamically significant rejection, coronary vasculopathy, and terminal cancer risk.
DOI: 10.1161/CIRCHEARTFAILURE.116.003265 -
Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy
A comprehensive meta-analysis of 29 randomized trials (266,148 patients) shows that baseline body mass index (BMI) modulates the cardiovascular benefit of intensive LDL-C lowering therapy, with the greatest reductions in cardiovascular and all-cause mortality observed in individ…
DOI: 10.1016/j.amjcard.2019.12.006 -
Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy
This study investigates the prevalence of healthy lifestyle factors among adults at high risk for atherosclerotic cardiovascular disease (ASCVD) who are candidates for statin therapy, finding that increased adherence to healthy lifestyles is associated with lower risks of incide…
DOI: 10.1016/j.ijcard.2016.01.001 -
Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study
A large Swedish cross-sectional register study in primary care shows many patients with coronary heart disease do not meet LDL-C targets or use adequate statin therapy, and modelling suggests that improved adherence and intensified statin regimens could substantially reduce 5-ye…
DOI: 10.1136/bmjopen-2020-036920 -
Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention
This review examines the association between statin therapy and the risk of new-onset diabetes, highlighting that while statins may increase diabetes risk, the cardiovascular benefits significantly outweigh this risk, particularly in individuals with pre-existing diabetes risk f…
DOI: 10.1007/s11886-024-02141-3 -
Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature
This 2013 comprehensive review synthesizes evidence from randomized trials and meta-analyses to evaluate whether statin therapy increases the risk of new-onset diabetes, its magnitude, potential mechanisms, and clinical implications, concluding a small increased risk that is gen…
DOI: 10.1111/dom.12254 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
Statins and new‐onset diabetes mellitus – a risk lacking in familial hypercholesterolaemia
This study investigates the relationship between statin use and the risk of new-onset diabetes mellitus (NOD) in patients with familial hypercholesterolemia, concluding that long-term statin therapy does not increase the risk of NOD in this population.
DOI: 10.1111/joim.12405